The role of matrix metalloproteinase-2 in the metastatic cascade: a review
Affiliation:
1. Minimal Residual Disease Laboratory, Faculty of Medicine , University Finis Terrae , Santiago , Chile 2. Department of Haematology , Hospital de Carabineros de Chile , Santiago , Chile
Abstract
Abstract
Matrix metalloproteinase-2 (MMP-2) is a gelatinase and is involved in multiple steps of the metastatic cascade. More than a decade ago an increased expression of MMP-2 in tumour cells or higher serum levels was reported to be a prognostic biomarker for a lower disease-free and overall survival rate. In recent years new evidence has indicated that MMP-2 has an important role in the tumour ecosystem. It is one of the many players in the onco-sphere, involved in interacting between tumour cells, host cells and the microenvironment. It plays a role in the dissemination of tumour cells, the epithelial–mesenchymal and mesenchymal–epithelial transitions, the formation of the pre-metastatic and metastatic niches, dormancy of tumour cells and modulating the immune system. The aim of this review is to highlight these multiple roles in the metastatic cascade and how many signalling pathways can up or down-regulate MMP-2 activity in the different stages of cancer progression and the effect of MMP-2 on the onco-sphere. Research in head and neck cancer is used as an example of these processes. The use of non-specific MMP inhibitors has been unsuccessful showing only limited benefits and associated with high toxicity as such that none have progressed past Phase III trials. Preclinical trials are undergoing using antibodies directed against specific matrix metalloproteinases, these targeted therapies may be potentially less toxic to the patients.
Publisher
Walter de Gruyter GmbH
Reference165 articles.
1. NIH. Minimal residual disease definition. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/minimal-residual-disease [Accessed July 2023]. 2. Xia, L, Mei, J, Kang, R, Deng, S, Chen, Y, Yang, Y, et al.. Perioperative ctDNA based molecular residual disease detection for non-small cell lung cancer: a prospective multicentre cohort study (LUNGCA-1). Clin Cancer Res 2022;28:3308–17. https://doi.org/10.1158/1078-0432.ccr-21-3044. 3. Zhong, R, Gao, R, Fu, W, Li, C, Huo, Z, Gao, Y, et al.. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis. Biomed Chromatogr 2023;21:180. https://doi.org/10.1186/s12916-023-02849-z. 4. Raza, A, Khan, AQ, Inchakalody, VP, Mestiri, S, Safira, Z, Yoosuf, KM, et al.. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. J Exp Clin Cancer Res 2022;41:99. https://doi.org/10.1186/s13046-022-02318-0. 5. Murray, NP, Aedo, S, Villalon, R, Albarran, V, Orrego, S, Guzman, E. Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. Ecancermedicalscience 2020;14:1119. https://doi.org/10.3332/ecancer.2020.1119.
|
|